Summary

The use of specialized blood products in patients with hematologic malignancies is an important part of the therapeutic and supportive care of these patients. While the indications for red cell transfusion are essentially the same for any patient who has anemia, platelets and other specialized components have unique requirements in this group of patients. The ready availability of leukocyte-reduced and/or irradiated blood components are essential elements for optimal patient care. Close cooperation and consultation between the treating physicians and the transfusion service are critical, as these patients can present many transfusion-related challenges. Transfusion medicine specialists should be readily available for consultation.

14. Lee JH, Lee JH, Choi SJ, et al.: Changes in isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 120:702-710, 2003.

15. de la Rubia J, Arriaga F, Andreu R, et al.: Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation: is ABO incompatibility a predisposing factor? Transfusion 41:106-110, 2001.

16. Sokol RJ, Stamps R, Booker DJ, et al.: Posttransplant immune-mediated hemolysis. Transfusion 42:198-204, 2002.

17. Mytilineos ALJ, Voso MT, Weber-Nordt R, Liebisch P, Lensing C, Schraven B: Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jka after allogeneic PBPC transplantation. Transfusion 40:632-636, 2000.

18. Slichter SJ: Controversies in platelet transfusion therapy. Ann Rev Med 31:509-540, 1980.

19. Hussein MA, Hoeltge GA: Platelet transfusion therapy for medical and surgical patients. Clev Clin J Med 63:245-250, 1996.

20. Davis KB, Slichter SJ, Corash L: Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39:586-592, 1999.

21. Slichter SJ: Platelet transfusion therapy. Hematol Oncol Clin North Am 4:291-311, 1990.

22. Schiffer CA, Anderson KC, Bennett CL, et al.: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001.

23. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 122:10-23, 2003.

24. Wandt H, Frank M, Ehninger G, et al.: Safety and cost effectiveness of a 10 X 109/L trigger for prophylactic platelet transfusions compared with the traditional 20 X 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91: 3601-3606, 1998.

25. Lawrence JB, Yomtovian RA, Hammons T, et al.: Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 41:67-76, 2001.

26. Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA: Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 127:409-414,

Was this article helpful?

0 0

Post a comment